These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37614155)

  • 1. Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.
    Newton H; Miller-Rosales C; Crawford M; Cai A; Brunette M; Meara E
    Psychiatr Serv; 2024 Feb; 75(2):182-185. PubMed ID: 37614155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of availability of long-acting medication for opioid use disorder.
    Shover CL; Humphreys K
    Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder.
    Alinsky RH; Hadland SE; Matson PA; Cerda M; Saloner B
    J Adolesc Health; 2020 Oct; 67(4):542-549. PubMed ID: 32336560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accountability across the Continuum: The Participation of Postacute Care Providers in Accountable Care Organizations.
    Colla CH; Lewis VA; Bergquist SL; Shortell SM
    Health Serv Res; 2016 Aug; 51(4):1595-611. PubMed ID: 26799992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder.
    Andraka-Christou B; Nguyen T; Bradford DW; Simon K
    J Subst Abuse Treat; 2020 Mar; 110():49-58. PubMed ID: 31952628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provision of Digital Health Technologies for Opioid Use Disorder Treatment by US Health Care Organizations.
    Miller-Rosales C; Morden NE; Brunette MF; Busch SH; Torous JB; Meara ER
    JAMA Netw Open; 2023 Jul; 6(7):e2323741. PubMed ID: 37459098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
    Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
    Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis.
    Solomon KT; Bandara S; Reynolds IS; Krawczyk N; Saloner B; Stuart E; Connolly E
    J Subst Abuse Treat; 2022 Jan; 132():108424. PubMed ID: 34144299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
    Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
    J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.
    Cantor J; Powell D; Kofner A; Stein BD
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109107. PubMed ID: 34656034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.